Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;35:108-112

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katakam, P. V. G.
Right arrow Articles by Miller, A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katakam, P. V. G.
Right arrow Articles by Miller, A. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*METFORMIN HYDROCHLORIDE
*NITRIC OXIDE
Related Collections
Right arrow Animal models of human disease
Right arrow Hypertension - basic studies
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2000;35:108.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Metformin Improves Vascular Function in Insulin-Resistant Rats

Prasad V. G. Katakam; Michael R. Ujhelyi; Margarethe Hoenig; Allison W. Miller

From the University of Georgia Colleges of Pharmacy (P.V.G.K., M.R.U., A.W.M.) and Veterinary Medicine (M.H.), Medical College of Georgia School of Medicine (M.R.U., A.W.M.), and Augusta VA Medical Center (P.V.G.K., M.R.U., A.W.M.), Augusta, Ga.

Correspondence to Dr Allison W. Miller, Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157. E-mail amiller{at}wfubmc.edu

Abstract—This study assessed the effect of metformin treatment on insulin, mean arterial pressure (MAP), and endothelial function in insulin-resistant (IR) rats. In addition, we assessed the direct effect of metformin in vitro. Sprague-Dawley rats were randomized to control (n=28) or IR (n=28) groups. Rats were further randomized to receive metformin (300 mg/kg) or placebo for 2 weeks. MAP and insulin were measured. Subsequently, a third-order branch of the superior mesenteric artery was isolated, and endothelial function was assessed. Specifically, dose-response experiments of acetylcholine (ACh) with or without N-nitro-L-arginine (LNNA) were performed. For in vitro experiments, mesenteric arteries were removed from untreated control and IR rats and treated with metformin (100 µmol/L) before ACh±LNNA. MAP and insulin levels were improved in IR-metformin compared with IR-placebo rats. Maximal relaxation (Emax) to ACh was enhanced in IR-metformin (92±2%) compared with IR-placebo rats (44±4%) (P<0.05). Relaxation in response to ACh+LNNA was greater in IR-metformin (33±4%) than in IR-placebo rats (12±4%) but remained depressed compared with control rats (Emax=68±5%). The control group was not affected by metformin. In vitro treatment of arteries with metformin in response to ACh produced results similar to those in the experiments with metformin-treated rats. Although metformin improves metabolic abnormality in IR rats, this action does not appear to mediate its effect on vascular function. Both in vivo and in vitro metformin improved ACh-induced relaxation in IR rats to control levels, apparently through nitric oxide–dependent relaxation. These data suggest that metformin improves vascular function through a direct mechanism rather than by improving metabolic abnormalities.


Key Words: insulin resistance • relaxation • metformin • nitric oxide • blood pressure




This article has been cited by other articles:


Home page
CirculationHome page
H. Sasaki, H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, et al.
Metformin Prevents Progression of Heart Failure in Dogs: Role of AMP-Activated Protein Kinase
Circulation, May 19, 2009; 119(19): 2568 - 2577.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata
Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Sydow, C. E. Mondon, J. Schrader, H. Konishi, and J. P. Cooke
Dimethylarginine Dimethylaminohydrolase Overexpression Enhances Insulin Sensitivity
Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 692 - 697.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Z. Xie, Y. Dong, R. Scholz, D. Neumann, and M.-H. Zou
Phosphorylation of LKB1 at Serine 428 by Protein Kinase C-{zeta} Is Required for Metformin-Enhanced Activation of the AMP-Activated Protein Kinase in Endothelial Cells
Circulation, February 19, 2008; 117(7): 952 - 962.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M.-J. Lee, D. Feliers, M. M. Mariappan, K. Sataranatarajan, L. Mahimainathan, N. Musi, M. Foretz, B. Viollet, J. M. Weinberg, G. G. Choudhury, et al.
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy
Am J Physiol Renal Physiol, February 1, 2007; 292(2): F617 - F627.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
L. G. K. de Aguiar, L. R. Bahia, N. Villela, C. Laflor, F. Sicuro, N. Wiernsperger, D. Bottino, and E. Bouskela
Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance
Diabetes Care, May 1, 2006; 29(5): 1083 - 1089.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
B. J. Davis, Z. Xie, B. Viollet, and M.-H. Zou
Activation of the AMP-Activated Kinase by Antidiabetes Drug Metformin Stimulates Nitric Oxide Synthesis In Vivo by Promoting the Association of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase
Diabetes, February 1, 2006; 55(2): 496 - 505.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. D'Angelo, A. A. Elmarakby, D. M. Pollock, and D. W. Stepp
Fructose Feeding Increases Insulin Resistance but Not Blood Pressure in Sprague-Dawley Rats
Hypertension, October 1, 2005; 46(4): 806 - 811.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
K. Sydow, C. E Mondon, and J. P Cooke
Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
Vascular Medicine, July 1, 2005; 10(1_suppl): S35 - S43.
[Abstract] [PDF]


Home page
Vasc MedHome page
K. Sydow, C. E Mondon, and J. P Cooke
Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
Vascular Medicine, May 1, 2005; 10(2_suppl): S35 - S43.
[Abstract] [PDF]


Home page
DiabetesHome page
A. Gallo, G. Ceolotto, P. Pinton, E. Iori, E. Murphy, G. A. Rutter, R. Rizzuto, A. Semplicini, and A. Avogaro
Metformin Prevents Glucose-Induced Protein Kinase C-{beta}2 Activation in Human Umbilical Vein Endothelial Cells Through an Antioxidant Mechanism
Diabetes, April 1, 2005; 54(4): 1123 - 1131.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-H. Zou, S. S. Kirkpatrick, B. J. Davis, J. S. Nelson, W. G. Wiles IV, U. Schlattner, D. Neumann, M. Brownlee, M. B. Freeman, and M. H. Goldman
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo: ROLE OF MITOCHONDRIAL REACTIVE NITROGEN SPECIES
J. Biol. Chem., October 15, 2004; 279(42): 43940 - 43951.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D.-S. Wang, H. Kusuhara, Y. Kato, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama
Involvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin
Mol. Pharmacol., April 1, 2003; 63(4): 844 - 848.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D.-S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama
Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 510 - 515.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Severino, P. Brizzi, A. Solinas, G. Secchi, M. Maioli, and G. Tonolo
Low-dose dexamethasone in the rat: a model to study insulin resistance
Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E367 - E373.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers
Metformin: An Update
Ann Intern Med, July 2, 2002; 137(1): 25 - 33.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. J. Mather, S. Verma, and T. J. Anderson
Improved endothelial function with metformin in type 2 diabetes mellitus
J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1344 - 1350.
[Abstract] [Full Text] [PDF]